This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027. Patients who are more obese may ultimately do better with Zepbound, said ...

GLP-1 medications for weight loss are all the rage, but they come with some side effects. Here are my top 10 supplements I take everyday while on Zepbound.

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $943.0, a high ...

Retirement dreams often hinge on a robust portfolio, with $1 million as a coveted benchmark for financial security. Achieving ...

It would behoove more Americans to learn how consistent seafood consumption has strong potential to ward off coronary disease ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Lilly to offer all doses of Zepbound vials at $499 ... a pharmaceutical giant with a market capitalization of $735 billion and an "GREAT ... could significantly impact the company’s position in ...